Point mutations of protein kinases and individualised cancer therapy

Michael Davies, Bryan Hennessy, Gordon Mills

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

The treatment of cancer is rapidly changing, with an increasing focus on converting our improved understanding of the molecular basis of disease into clinical benefit for patients. Protein kinases that are mutated in cancer represent attractive targets, as they may result in cellular dependency on the mutant kinase or its associated pathway for survival, a condition known as 'oncogene addiction'. Early clinical experiences have demonstrated dramatic clinical benefit of targeting oncogenic mutations in diseases that have been largely resistant to traditional cytotoxic chemotherapy. Further, mutational activation of kinases can indicate which patients are likely to respond to targeted therapeutics. However, these experiences have also illuminated a number of critical challenges that will have to be addressed in the development of effective drugs across different cancers, to fully realise the potential of individualised molecular therapy. This review utilises examples of genetic activation of kinases to illustrate many of the lessons learned, as well as those yet to be implemented.

Original languageEnglish (US)
Pages (from-to)2243-2261
Number of pages19
JournalExpert Opinion on Pharmacotherapy
Volume7
Issue number16
DOIs
StatePublished - Nov 1 2006
Externally publishedYes

Fingerprint

Point Mutation
Protein Kinases
Phosphotransferases
Neoplasms
Oncogenes
Therapeutics
Drug Therapy
Mutation
Survival
Pharmaceutical Preparations

Keywords

  • Acute myelogenous leukaemia
  • b-Raf
  • c-Kit
  • EGFR
  • Erlotinib
  • Flt-3
  • Gastrointestinal stromal tumour
  • Gefitinib
  • High-throughput DNA sequencing
  • Imatinib mesilate
  • Jak-2
  • Myeloproliferative disorders
  • PIK3CA
  • Platelet-derived growth factor receptor-α

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Point mutations of protein kinases and individualised cancer therapy. / Davies, Michael; Hennessy, Bryan; Mills, Gordon.

In: Expert Opinion on Pharmacotherapy, Vol. 7, No. 16, 01.11.2006, p. 2243-2261.

Research output: Contribution to journalReview article

Davies, Michael ; Hennessy, Bryan ; Mills, Gordon. / Point mutations of protein kinases and individualised cancer therapy. In: Expert Opinion on Pharmacotherapy. 2006 ; Vol. 7, No. 16. pp. 2243-2261.
@article{956fe3a3e20a40798438a30abdc7720e,
title = "Point mutations of protein kinases and individualised cancer therapy",
abstract = "The treatment of cancer is rapidly changing, with an increasing focus on converting our improved understanding of the molecular basis of disease into clinical benefit for patients. Protein kinases that are mutated in cancer represent attractive targets, as they may result in cellular dependency on the mutant kinase or its associated pathway for survival, a condition known as 'oncogene addiction'. Early clinical experiences have demonstrated dramatic clinical benefit of targeting oncogenic mutations in diseases that have been largely resistant to traditional cytotoxic chemotherapy. Further, mutational activation of kinases can indicate which patients are likely to respond to targeted therapeutics. However, these experiences have also illuminated a number of critical challenges that will have to be addressed in the development of effective drugs across different cancers, to fully realise the potential of individualised molecular therapy. This review utilises examples of genetic activation of kinases to illustrate many of the lessons learned, as well as those yet to be implemented.",
keywords = "Acute myelogenous leukaemia, b-Raf, c-Kit, EGFR, Erlotinib, Flt-3, Gastrointestinal stromal tumour, Gefitinib, High-throughput DNA sequencing, Imatinib mesilate, Jak-2, Myeloproliferative disorders, PIK3CA, Platelet-derived growth factor receptor-α",
author = "Michael Davies and Bryan Hennessy and Gordon Mills",
year = "2006",
month = "11",
day = "1",
doi = "10.1517/14656566.7.16.2243",
language = "English (US)",
volume = "7",
pages = "2243--2261",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "16",

}

TY - JOUR

T1 - Point mutations of protein kinases and individualised cancer therapy

AU - Davies, Michael

AU - Hennessy, Bryan

AU - Mills, Gordon

PY - 2006/11/1

Y1 - 2006/11/1

N2 - The treatment of cancer is rapidly changing, with an increasing focus on converting our improved understanding of the molecular basis of disease into clinical benefit for patients. Protein kinases that are mutated in cancer represent attractive targets, as they may result in cellular dependency on the mutant kinase or its associated pathway for survival, a condition known as 'oncogene addiction'. Early clinical experiences have demonstrated dramatic clinical benefit of targeting oncogenic mutations in diseases that have been largely resistant to traditional cytotoxic chemotherapy. Further, mutational activation of kinases can indicate which patients are likely to respond to targeted therapeutics. However, these experiences have also illuminated a number of critical challenges that will have to be addressed in the development of effective drugs across different cancers, to fully realise the potential of individualised molecular therapy. This review utilises examples of genetic activation of kinases to illustrate many of the lessons learned, as well as those yet to be implemented.

AB - The treatment of cancer is rapidly changing, with an increasing focus on converting our improved understanding of the molecular basis of disease into clinical benefit for patients. Protein kinases that are mutated in cancer represent attractive targets, as they may result in cellular dependency on the mutant kinase or its associated pathway for survival, a condition known as 'oncogene addiction'. Early clinical experiences have demonstrated dramatic clinical benefit of targeting oncogenic mutations in diseases that have been largely resistant to traditional cytotoxic chemotherapy. Further, mutational activation of kinases can indicate which patients are likely to respond to targeted therapeutics. However, these experiences have also illuminated a number of critical challenges that will have to be addressed in the development of effective drugs across different cancers, to fully realise the potential of individualised molecular therapy. This review utilises examples of genetic activation of kinases to illustrate many of the lessons learned, as well as those yet to be implemented.

KW - Acute myelogenous leukaemia

KW - b-Raf

KW - c-Kit

KW - EGFR

KW - Erlotinib

KW - Flt-3

KW - Gastrointestinal stromal tumour

KW - Gefitinib

KW - High-throughput DNA sequencing

KW - Imatinib mesilate

KW - Jak-2

KW - Myeloproliferative disorders

KW - PIK3CA

KW - Platelet-derived growth factor receptor-α

UR - http://www.scopus.com/inward/record.url?scp=34248546062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248546062&partnerID=8YFLogxK

U2 - 10.1517/14656566.7.16.2243

DO - 10.1517/14656566.7.16.2243

M3 - Review article

VL - 7

SP - 2243

EP - 2261

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -